Two drugmakers join TrumpRx as guidelines push early
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- TrumpRx welcomes two more pharmaceutical partners, boosting its pipeline for ALS and other neurodegenerative therapies (STAT+).
- American Heart Association and other cardiology societies push cholesterol screening to age 30, shifting prevention earlier in life (STAT+).
- ALS advocacy groups caution that federal funding reductions could cripple ongoing research and delay new treatments (STAT+).
- Medical device manufacturers report that even after FDA clearance, Medicare reimbursement can take years, slowing patient access (STAT+).
Why it matters: Earlier heart prevention and expanded drug collaborations could save lives, but funding and reimbursement roadblocks threaten progress.
Ask SkimNews
